Committee for Advanced Therapies [CAT]

The EMA Committee for Orphan Medicinal Products (COMP) reviews applications for orphan-medicinal-product designation.

The EMA Committee for Advanced Therapies (CAT) reviews the quality, safety, and efficacy of Advanced-Therapy Medicinal Products (ATMPs).

This article explores patient involvement in scientific regulatory committees in the EU, specifically in the activities of the European Medicines Association (EMA).

A medicine can be marketed in the European Union (EU) until the company has obtained a Marketing Authorisation (MA) for that medicine from the relevant regulatory authority. MAs are granted for medicines that are proved to be safe, effective and of high quality.